NeuroSearch entered into a deal with GlaxoSmithKline (GSK) that provided GSK an option on compounds arising from NeuroSearch’s research into the use of triple action monoamine reuptake inhibitors to treat depression. NeuroSearch will receive up to US$27 M in pre-marking milestones and further undisclosed payments when GSK selects additional compounds for development. The article focuses on how this deal structure complements NeuroSearch’s existing portfolio of alliances and assesses the merits of the deal.